ReviewTherapeutic advances in neurological disorders2020
A critical appraisal of bypass surgery in moyamoya disease.
Review in Therapeutic advances in neurological disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Risk factors for perioperative cerebral infarction in moyamoya disease: a meta-analysis.Frontiers in neurology · 2025Pooled it
- A meta-analysis of comparisons of various surgical treatments for moyamoya diseases.Brain and behavior · 2021Pooled it
- Advances in cerebrovascular reserve function assessment for moyamoya disease.BMJ neurology open · 2026Review
- Intraoperative application of FFR pressure wire and FLOW800 imaging as predictors of postoperative cerebral perfusion abnormalities in Moyamoya disease.Frontiers in surgery · 2026Article
- Multisystemic Impact of RNF213 Arg4810Lys: A Comprehensive Review of Moyamoya Disease and Associated Vasculopathies.International journal of molecular sciences · 2025Review
- Temporal muscle thickness as a preoperative predictor of motor aphasia in Moyamoya disease.Frontiers in neurology · 2025Article
- Long-term outcomes after revascularization surgery for adult moyamoya disease: Protocol for systematic review and meta-analysis.PloS one · 2025Article
- Prediction of cerebral infarction after bypass surgery in adult moyamoya disease: using pulsatility index on TCD.BMC neurology · 2024Article
- Local transplantation of mesenchymal stem cells improves encephalo-myo-synangiosis-mediated collateral neovascularization in chronic brain ischemia.Stem cell research & therapy · 2023Article
- Postoperative cerebral infarction after revascularization in patients with moyamoya disease: Incidence and risk factors.Frontiers in neurology · 2022Article
- Use of a panel of four microRNAs in CSF as a predicted biomarker for postoperative neoangiogenesis in moyamoya disease.CNS neuroscience & therapeutics · 2021Article
- Moyamoya disease concurrent with dural arteriovenous fistula: A case report and literature review.Experimental and therapeutic medicine · 2020Article
- Preliminary comparison of efficacy and safety between direct bypass surgery and endovascular recanalization therapy in adult ischemic moyamoya disease.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moyamoya disease (MMD) is a complex cerebrovascular disorder about which little is known. Conventionally, revascularization surgery is recommended for patients, despite an absence of conclusive data from adequate clinical trials. Underscoring the uncertainty that exists in treating MMD patients, investigators continue to present data comparing revascularization with conservative or medical management, most of which originates from East Asia where MMD is most prevalent. The purpose of this manuscript is to review contemporary large case series, randomized trials, and recent meta-analyses that compare surgical and medical treatments in adult patients with MMD, and to critically analyze the modern literature in the context of current practice standards. Data from the available literature is limited, but revascularization seems superior to conservative therapy in adult patients presenting with hemorrhage, and in preventing future hemorrhages. Conversely, evidence that surgery is superior to medical therapy is not convincing in adult patients presenting with cerebral ischemia, or for the prevention of future ischemic events. In contrast to East Asian populations, MMD in Europe and in the Americas is predominantly an ischemic disease that presents in adulthood. Adequate multinational trials are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.